Nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of atherosclerotic cardiovascular disease. In our meta-analysis, we aimed to assess the correlation of NAFLD and four surrogate markers of subclinical atherosclerosis. PubMed, Embase, and the Cochrane Library were searched up until April 2017. Original studies investigating the association between NAFLD and subclinical atherosclerosis were included. The outcome data were extracted and pooled for the effect estimate by using a random-effects model. We used the Newcastle-Ottawa Quality Assessment Scale to assess the quality of the included studies. Of the 434 initially retrieved studies, 26 studies involving a total of 85,395 participants (including 29,493 patients with NAFLD) were included in this meta-analysis. The Newcastle-Ottawa Quality Assessment Scale scores suggested the included studies were of high quality. The pooled effects estimate showed that subjects with NAFLD exhibited a significant independent association with subclinical atherosclerosis compared to the non-NAFLD group (odds ratio, 1.60; 95% confidence interval, 1.45-1.78). Subgroup analysis suggested that the presence of NAFLD yielded a remarkable higher risk of increased carotid artery intima-media thickness/plaques, arterial stiffness, coronary artery calcification, and endothelial dysfunction with odds ratios (95% confidence interval) of 1.74 (1.47-2.06), 1.56 (1.24-1.96), 1.40 (1.22-1.60), and 3.73 (0.99-14.09), respectively. Conclusion: Our meta-analysis revealed a close link between NAFLD and subclinical atherosclerosis in light of four different indices. Patients with NAFLD might benefit from screening and surveillance of early atherosclerosis, which would facilitate the prediction of potential cardiovascular disease burden, risk stratification, and appropriate intervention in the long term. (Hepatology Communications 2018;2:376-392) 
Introduction N onalcoholic fatty liver disease (NAFLD) has become an emerging global public health concern, with prevalence estimates ranging from 10% to 30% in the general population and a higher prevalence of 40% to 70% in individuals with obesity or diabetes mellitus. (1) NAFLD is a condition histologically divided into nonalcoholic fatty liver (isolated steatosis with or without nonspecific inflammation) and nonalcoholic steatohepatitis (NASH), with varying degrees of hepatic fibrosis and more progressive natural history. (2) In recent years, NAFLD has also been recognized as the hepatic manifestation of metabolic syndrome, sharing a series of risk factors with cardiovascular disease (CVD), including insulin resistance, hypertension, obesity, and dyslipidemia. (3) Epidemiologic evidence from the early to mid-2000s indicated that CVD events had increased and was presenting as the most common cause of death in patients with NAFLD (approximately 25%). (4) As such, early evaluation for CVD in a preclinical stage in the high-risk population is necessary to decrease cardiovascular morbidity and mortality.
Additionally, a growing body of evidence demonstrated that NAFLD not only behaved as a marker of atherosclerotic CVD but also might take part in its pathogenesis, providing insight regarding the relationship between NAFLD and early stage atherosclerosis. (5, 6) Notably, a spectrum of studies reported that NAFLD is associated with markers of preclinical atherosclerosis, independent of traditional risk factors. (7) At present, carotid artery intima-media thickness (CIMT), arterial stiffness (AS), coronary artery calcification (CAC), and brachial arterial flow-mediated dilation (FMD) are noninvasive techniques that generally serve as surrogate markers for subclinical atherosclerosis. They are used during initial assessment of potential cardiovascular events and risk stratification to determine appropriate therapeutic strategies for patients with latent CVD.
In this context, it is plausible that there is a relationship between the presence of NAFLD and subclinical atherosclerosis. A systematic review highlighted the association of NAFLD with various indices of subclinical atherosclerosis independent of established CVD risk factors. Unfortunately, that study failed to offer the effect estimates of the correlation, and uncertainty still exists with respect to the potential link between NAFLD and the aforementioned markers of subclinical atherosclerosis. We therefore performed a systematic review and meta-analysis to attain a comprehensive understanding of this issue.
Materials and Methods

SEARCH STRATEGY
The protocol for this systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. (8) PubMed, Embase, and the Cochrane Library databases were extensively searched up until April 30, 2017 , to identify potentially relevant publications without language or date restrictions. Medical subject heading terms were "nonalcoholic fatty liver disease" or "NAFLD" or "fatty liver" and "cardiovascular disease" or "subclinical atherosclerosis" or "preclinical atherosclerosis" or "intima-media thickness" or "coronary calcification" or "coronary artery calcification" or "endothelial dysfunction" or "arterial stiffness" or "flow-mediated dilation" or "pulse wave velocity." Reference lists from cited articles were also manually searched for additional eligible trials.
(ORs) or hazard ratios with confidence intervals (CIs) were provided or could be estimated with sufficient information; (4) diagnosis of NAFLD was based on ultrasound, computed tomography, or biopsy. Duplicated or overlapping reports were deleted if referring to the same title, author list, or publication date.
STUDY SELECTION AND DATA EXTRACTION
After the first screening of titles/abstracts, full articles of potentially eligible studies were independently reviewed by two investigators (Y.Z., X.Z.) with regard to the inclusion and exclusion criteria. The following relevant information of included studies was extracted: 1) study: the first author, year of publication, location, design; 2) participants: number, age, and sex of the NAFLD and non-NAFLD groups; 3) evaluation methods of NAFLD and subclinical atherosclerosis; 4) adjusted confounders. Conventionally, the most adjusted estimate was selected when a study offered more than one risk estimate. Any discrepancies regarding the extraction of data were resolved by an additional investigator (M.Z.).
QUALITY ASSESSMENT
The methodologic quality of the included studies was evaluated by a "star system" based on the Newcastle-Ottawa Quality Assessment Scale, which ranged from one to nine stars and consisted of three items: (1) patient selection; (2) comparability of groups or cohorts; (3) assessment of either the exposure or outcome of interest for case-control or cohort studies, respectively. Two reviewers (Y.Z., X.Z) independently assessed the quality of the original article, with a third author addressing any subsequent disagreements.
STATISTICAL ANALYSIS
The results of studies were pooled, and an overall estimate of ORs or hazard ratios with 95% CI were obtained. In the inverse variance approach, the weight given to each study is the inverse of the variance of the effect estimate (i.e., 1 over the square of its SEM). Clinical heterogeneity was assessed by the v 2 test and quantified by the I 2 statistic, which was minimal if <25%, moderate if 25%-49%, and substantial if >50%. In light of the significant heterogeneity among studies, a random-effects model by the Der Simonian and Laird method was used, resulting in a more conservative estimate compared to the fixed-effects model. Two sources of variability in effects are assumed for weight in the inverse variance method with the random-effects model; one is from sampling error and the other from study-level differences, which represent the effects from variability across the population. Subgroup analysis was further conducted according to the following diagnostic indices of subclinical atherosclerosis: CIMT, CAC or plaques, AS, and FMD. Additionally, a sensitivity analysis was carried out by removing each individual study at a time and determining its effect on the ultimate effect estimate. P < 0.05 was considered statistically significant for all analyses. Funnel plots and Egger's regression test were performed to check for publication bias. Statistical analyses were performed with Review Manager version 5.3. 
Results
SEARCH RESULTS
The PRISMA flowchart of the literature search process is shown in Fig. 1 .
Electronic and manual searches retrieved 434 potentially relevant publications, which after the initial screening resulted in removing 208 papers according to title and abstract. By reviewing the full articles, 178 papers were further excluded because (1) data were unavailable for a risk estimate (e.g., quantitative variables); (2) there were no outcome data of interest; or (3) the study was considered a basic research study/ review article or not related. Eventually, 26 unique clinical studies were eligible for inclusion in this metaanalysis. 
BASELINE CHARACTERISTICS OF THE STUDIES
The main characteristics of the qualified studies in this meta-analysis are summarized in Table 1 . Overall, our analysis included 26 observational studies enrolling a total of 85,395 participants (including 29,493 patients with NAFLD). In both the NAFLD and non-NAFLD groups, most subjects were middle-aged male individuals, although two studies focused on the pediatric population. These studies were carried out in Asia (China, India, South Korea, Turkey, Iran, Israel, and Japan), Europe (Spain, Italy, Finland, Germany, and Sweden), and America (United States and Brazil). Among them, CIMT/carotid plaques, CAC, AS, and FMD were widely employed as surrogate markers of subclinical atherosclerosis. Twenty studies were crosssectional studies, four studies were case-control studies, and two were prospective cohort studies (either population-based or hospital-based or outpatient cohorts). The majority of studies used ultrasonography or computed tomography for diagnosis of NAFLD, and four studies were based on liver biopsy. The Newcastle-Ottawa Quality Assessment Scale scores suggested the included studies were of high quality ( Table 2) .
RELATIONSHIP BETWEEN NAFLD AND SUBCLINICAL ATHEROSCLEROSIS
Overall, the mosaic plot revealed that, compared to subjects without NAFLD, patients with NAFLD exhibited a significant higher risk of subclinical atherosclerosis in light of four different indices with OR (CI) values of 1.60 (1.45-1.78) (Fig. 2) . We found evidence of heterogeneity across the included studies (I 2 5 82%; P < 0.05), and an exclusion sensitivity analysis did not alter the above results. We then conducted a subgroup analysis for four types of indices accounting for subclinical atherosclerosis as mentioned below.
Thirteen studies with 12,269 individuals were included that addressed CIMT/carotid plaques. Pooled data suggested that NAFLD was associated with a remarkably higher likelihood of pathologic CIMT/carotid plaques (OR, 1.74; 95% CI, 1.47-2.06; P < 0.00001; I 2 5 86%) (Fig. 3) . Additionally, data on CAC were available for analysis from seven studies with 29,531 participants. The pooled analysis showed that NAFLD was significantly associated with a higher likelihood of increased CAC Abbreviations: ab, antibody; ALT, alanine aminotransferase; AST, aspartate transaminase; BP, blood pressure; BMI, body mass index; CAD, coronary artery disease; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; GGT, gamma-glutamyl transferase; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HDL, highdensity lipoprotein; HDL-C, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus; HR, heart rate; hsCRP, high-sensitivity C-reactive protein; HU, Hounsfield unit; MetS, metabolic syndrome; NA, not available; NAFLD, nonalcoholic fatty liver disease; sCr, serum creatinine; SBP, systolic blood pressure; SDS, standard deviation score; WC, waist circumference. SDS
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or plaques (OR, 1.40; 95% CI, 1.22-1.60; P 50.02; I 2 5 59%) (Fig. 4) . Four observational studies with 43,169 subjects were involved for AS. Compared with the non-NAFLD group, the presence of NAFLD was significantly associated with a higher likelihood of AS (OR,1.56; CI, 1.24-1.96). Potential heterogeneity across studies was observed (I 2 5 65%; P 5 0.03) (Fig. 5) . We found three studies referring to FMD with available data from 426 participants. The likelihood of impaired FMD was higher in the NAFLD group compared to the non-NAFLD group (OR, 3.73; 95% CI, 0.99-14.09) with substantial heterogeneity (I 2 5 67%) (Fig. 6) .
Discussion
We revealed a close link between NAFLD and subclinical atherosclerosis in this systematic review and meta-analysis based on 26 observational studies involving a total of 85,395 participants and 29,493 NAFLD A. Carotid intimal-medial thickness or plaques 2011 (10) * * * ** * * * ******** 2008 (11) FIG. 2. Mosaic plot showing that patients with NAFLD exhibited a significant higher risk of subclinical atherosclerosis compared to subjects without NAFLD. cases. Notably, subgroup analysis yielded a consistent result in the four different methods of CIMT/carotid plaques, CAC or plaques, AS, and FMD, albeit with substantial heterogeneity and potential publication bias. These findings are in agreement with a previous meta-analysis assessing the correlation between NAFLD and pathologic CIMT (OR, 2.04; 95% CI, 1.65-2.51) and carotid plaques (OR, 2.82; 95% CI, 1.87-4.27). (7) This is in contrast to patients with diabetes; however, no significant association was found between hepatic steatosis and CIMT/carotid calcium. (36) (37) (38) Despite these controversial findings, our results are in line with a majority of epidemiologic studies demonstrating that NAFLD is closely associated with increased CIMT, AS, CAC score, and impaired endothelial function. (39) This association is more prominent and significant in increased CIMT/ plaque than other indicators of subclinical atherosclerosis. Although several meta-analyses previously evaluated the association between NAFLD and individual indexes of subclinical atherosclerosis (CIMT, carotid plaque, and CAC), none provided a comprehensive determination with respect to carotid atherosclerosis, AS, CAC, or endothelial dysfunction.
CIMT, assessed by B-mode ultrasound, may be used as a radiologic modality to demonstrate the presence and progression of subclinical atherosclerosis. (40) Carotid atherosclerosis serves as a mirror of the generalized atherosclerotic burden, reflecting the probability of the presence of atherosclerotic lesions and structural abnormalities in other arteries. (11) It correlates to the total number of vascular risk factors linearly and the prevalence and incidence of myocardial infarction and stroke and could facilitate early discrimination of patients likely to benefit from aggressive preventive measures.
AS is a reliable parameter of atherosclerotic vascular damage and early structural and functional arterial wall alteration, including high central pulse pressure, arterial remodeling, fat accumulation, inflammation, progression of stenosis, and plaques. (41) Increasing systolic and pulse pressure is evaluated by measuring pulse wave velocity between two sites in the arterial tree, with a higher index indicating stiffer arteries; increasing epidemiologic evidence has suggested its significant association with CVD and NAFLD. (29) As a low-cost feasible method, the prognostic value of AS for cardiovascular events is well accepted in routine clinical practice, even for individuals who are asymptomatic.
The CAC score is validated as an excellent marker for the presence and instability of atherosclerotic plaque. As the predominant pathologic substrate of CVD, a vulnerable plaque is potentially related to myocardial infarction and cardiac death. Considering that the CAC score could indirectly reflect the total plaque burden, it is not surprising that a high CAC score is an independent predictor of CVD events after accounting for conventional risk factors. (42) Previous studies suggested a linear relationship between the extent of the CAC score and all-cause mortality, thus improving the sensitivity to predict severe coronary atherosclerosis if combined with the Framingham score. (43) Endothelial dysfunction is a systemic pathologic state contributing to an imbalance between vasodilative and vasoconstrictive substances. FMD is assessed by high-resolution ultrasonography, reflecting coronary endothelium-dependent vasodilator function. (44) An impaired FMD response indicates early functional and structural changes in the vascular endothelium. It plays an important part in the pathogenesis and clinical manifestations of atherosclerosis, yielding additive prognostic information of long-term overt CVD events, even in a low-risk population. Recent studies have shown that patients with NAFLD were significantly linked to endothelial dysfunction, which is potentially responsible for CVD in the long term. (32, 34) The current understanding of the pathophysiology of NAFLD is based on the "multiple-hits hypothesis." The first hit initiates from simple steatosis as a consequence of insulin resistance and excessive lipid accumulation in hepatocytes. The second hit is the process involving oxidative stress and alteration of adipokines, contributing to the pathogenesis of NASH. The hepatocytes are then susceptible to multiple overwhelming insults, which lead to progressive liver disease, such as cirrhosis, liver failure, and ultimately hepatocellular carcinoma. (45) Accumulating evidence suggests that NAFLD is not merely affected by insulin resistance but also could act as a stimulus for further insulin resistance and metabolic syndrome in turn, thus paving the path for the development and progression of atherosclerosis and overt CVD events. (46) The biological mechanisms underlying the correlation between NAFLD and atherosclerosis remain to be elucidated. NASH and atherosclerosis were suggested as two aspects of a shared disease with a common etiology involving metabolic and inflammatory factors. (47) However, overwhelming evidence suggests that NAFLD is unlikely to be an innocent bystander in the progression of atherosclerosis. Instead, the proatherogenic effect of NAFLD is implicated in the interplay between insulin resistance, abnormal lipoprotein metabolism, chronic low-grade inflammation, excessive oxidative stress, and decreased adiponectin concentrations. Particularly, NAFLD renders a higher oxidative inflammatory response in the arterial wall, which may cause endothelial dysfunction and AS. (30) In addition, plasminogen activator inhibitor-1 and angiotensin II could exert a proatherogenic effect on blood vessels in patients with NAFLD. Further research is required to gain more insights into the crosstalk between NAFLD and atherosclerotic CVD.
Our meta-analysis should be interpreted in view of certain limitations. First, the majority of the included studies in this analysis are observational rather than prospective studies, and this might affect the validity of the overall results. In particular, the cross-sectional design fails to identify causal or temporal relationships between NAFLD and the development of subclinical atherosclerosis. Furthermore, data referring to the assessment of subclinical atherosclerosis from crosssectional studies and prospective cohort studies might convey different information. Specifically, crosssectional studies were more likely to be a single point on a subclinical atherosclerosis versus time curve, whereas the latter were more likely to correlate with the slope of that curve. Thus, processing progression data separately from cross-sectional data would provide more useful information if more prospective cohort studies are available in the future. Given the hospitalbased nature of most included studies, it is also inevitably prone to selection bias and might lead to an overestimate of the effect. Second, the diagnostic criteria of subclinical atherosclerosis and the definition for NAFLD in each included study are not unified, and this might be responsible for the inevitable clinical heterogeneity in this meta-analysis. Specifically, ultrasonography and computed tomography are the most common modalities for diagnosing NAFLD in the included studies, and this could lead to potential falsenegative results. Although ultrasonography is recommended as the first-line noninvasive tool for diagnosis of NAFLD, it is less sensitive (60%-90%) when hepatic fat infiltration is below approximately 30%. (48) Due to invasiveness and ethical considerations, liver biopsy is still infrequently performed in clinical practice even though it is the gold standard for evaluating the severity of NAFLD. Third, the presence of heterogeneity might restrict the interpretation of the effect estimates and give misleading results that might have been used in the random-effects model. The diversity in study design, surrogates of subclinical atherosclerosis, and ethnic and population characteristics are potentially responsible for a substantial heterogeneity across studies. Additionally, we were not able to exclude potential residual confounders, such as a history of medications, socioeconomic status, and lifestyle. Finally, possible publication bias exists according to the asymmetric funnel plot. Thus, the findings provided by this meta-analysis should be interpreted with caution.
Taken together, the present study demonstrates an independent correlation between NAFLD and subclinical atherosclerosis. The clinical implication of our results might consider patients with NAFLD to be recognized as at a high risk of atherosclerotic CVD. Awareness of the association is important for clinicians when various indices accounting for subclinical atherosclerosis are feasible in clinical practice. Future studies are still needed to further elucidate whether the association is derived from an overlapping etiology or if NAFLD contributes to a substantial risk of atherosclerosis progression. Hence, patients with NAFLD may benefit from early evaluation of atherosclerosis, thus facilitating prediction of CVD morbidity and mortality, risk stratification for appropriate intervention, and improvement of long-term clinical outcomes.
